[Dipeptidyl peptidase-4 inhibitors in type 2 diabetic elderly patient]

Jean Doucet, Bernard Bauduceau, Jean-Frédéric Blicklé
Gériatrie et Psychologie Neuropsychiatrie du Vieillissement 2011, 9 (2): 157-62
The increase in prevalence and the particularities of care in old diabetic patients, which accumulate consequences of both, age and diabetes, the treatment must be well tolerated. The main adverse event is a hypoglycemia risk because of its major consequences for the elderly diabetic subjects. Since few years, three dipeptydil-peptidase-4 inhibitors (DPP-4), for which some studies have included type 2 diabetic old subjects are available in Europe. Their efficiency and their tolerance do not differ significantly from those noted at the younger diabetics. The reduced risk of hypoglycemia and the absence of influence on the weight are two interesting arguments to use them in the old diabetic patients. It remains however necessary to realize studies led specifically to old and even oldest subjects, corresponding to those in daily practice. If the data on their tolerance is confirmed, it could intend to revise therapeutic target for the old diabetic patients.


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"